Article ID Journal Published Year Pages File Type
8744992 Clinical Microbiology and Infection 2017 30 Pages PDF
Abstract
Health systems have a finite and decreasing resource, decision makers currently do not have necessary evidence to assess whether AMS programmes provide sufficient benefits. Although the evidence-base of the cost-effectiveness of AMS is increasing, it remains inadequate for investment decision-making. Robust health economics research needs to be completed to enhance the generalizability and usability of cost-effectiveness results.
Related Topics
Life Sciences Immunology and Microbiology Microbiology
Authors
, , , , , ,